AR091464A1 - Compuestos biciclicos de tiofenilamida - Google Patents
Compuestos biciclicos de tiofenilamidaInfo
- Publication number
- AR091464A1 AR091464A1 ARP130102125A AR091464A1 AR 091464 A1 AR091464 A1 AR 091464A1 AR P130102125 A ARP130102125 A AR P130102125A AR 091464 A1 AR091464 A1 AR 091464A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- cycloalkyl
- carbon atoms
- attached form
- heterocycloalkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 17
- 125000004432 carbon atom Chemical group C* 0.000 abstract 13
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 13
- 125000003107 substituted aryl group Chemical group 0.000 abstract 11
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 125000005346 substituted cycloalkyl group Chemical group 0.000 abstract 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 101100226596 Gallus gallus FABP gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/66—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Composiciones que incluyen los compuestos y métodos de uso de los compuestos para diabetes tipo 2, aterosclerosis, cáncer, esteatohepatitis, enfermedades renales crónicas. Son inhibidores de las proteínas FABP 4 y/o 5. Reivindicación 1: Compuestos de la fórmula (1) en la que: R¹ y R² juntos forman un -CR¹⁴=CR¹⁵-CR¹⁶=CR¹⁷-, -CR¹⁴R¹⁵-O-(CR¹⁶R¹⁷)ₘ-CR¹⁸R¹⁹-, -CR¹⁴R¹⁵-(CR¹⁶R¹⁷)ₘ-O-CR¹⁸R¹⁹, -O-CR¹⁴R¹⁵-(CR¹⁶R¹⁷)ₘ-CR¹⁸R¹⁹-, -CR¹⁴R¹⁵-NR²²-CR¹⁶R¹⁷-CR¹⁸R¹⁹-, -CR¹⁴R¹⁵-S(O)₂-CR¹⁶R¹⁷-CR¹⁸R¹⁹-, -CR¹⁴R¹⁵-CR²⁰R²¹- o -CR¹⁴R¹⁵-CR¹⁶R¹⁷-(CR¹⁸R¹⁹)ₚ-CR²⁰R²¹-; R³ es un arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²³ y también pueden estar sustituidos por R²⁴ y/o R²⁵; R⁴ es H o alquilo; R⁵ y R⁶ se eligen con independencia entre H, alquilo y cicloalquilo; R⁷ es H, alquilo o cicloalquilo; A es NR⁸ o CR⁹R¹⁰; E es NR¹¹ o CR¹²R¹³; R⁸ y R¹¹ se eligen con independencia entre H, alquilo y cicloalquilo; R⁹, R¹⁰, R¹² y R¹³ se eligen con independencia entre H, halógeno, alquilo, haloalquilo y cicloalquilo; o R⁵ y R¹² junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁶ y también pueden estar sustituidos por R²⁷ y/o R²⁸, pero en el caso de que R⁵ y R¹² junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R⁶ y R¹³ estarán ausentes; o R⁸ y R¹² junto con los átomos de nitrógeno y de carbono a los que están unidos forman un heterocicloalquilo sustituido o heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁶ y también pueden estar sustituidos por R²⁷ y/o R²⁸, pero en el caso de que R⁸ y R¹² junto con los átomos de carbono a los que están unidos formen un heteroarilo sustituido, entonces R¹³ estará ausente; o R⁹ y R¹¹ junto con los átomos de nitrógeno y de carbono a los que están unidos forman un heterocicloalquilo sustituido o heteroarilo sustituido, dichos heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁶ y también pueden estar sustituidos por R²⁷ y/o R²⁸, pero en el caso de que R⁹ y R¹¹ junto con los átomos de carbono a los que están unidos formen un heteroarilo sustituido, entonces R¹⁰ estará ausente; o R⁹ y R¹² junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁶ y también pueden estar sustituidos por R²⁷ y/o R²⁸, pero en el caso de que R⁹ y R¹² junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R¹⁰ y R¹³ estarán ausentes; o R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos forman un cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido o heteroarilo sustituido, dichos cicloalquilo sustituido, arilo sustituido, heterocicloalquilo sustituido y heteroarilo sustituido están sustituidos por R²⁹ y también pueden estar sustituidos por R³⁰ y/o R³¹, pero en el caso de que R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos formen un arilo sustituido o heteroarilo sustituido, entonces R⁹ y R¹² estarán ausentes; o R¹⁰ y R¹³ junto con los átomos de carbono a los que están unidos forman un doble enlace; R¹⁴, R¹⁵, R¹⁶, R¹⁷, R¹⁸, R¹⁹, R²⁰, R²¹, R²³, R²⁴, R²⁵, R²⁶, R²⁷, R²⁸, R²⁹, R³⁰ y R³¹ se eligen con independencia entre H, oxo, hidroxi, halógeno, alquilo, cicloalquilo, haloalquilo, alcoxi, alcoxialquilo, alcoxicarbonilo y carboxi; o R¹⁶ y R¹⁷ junto con los átomos de carbono a los que están unidos forman un cicloalquilo o heterocicloalquilo; o R¹⁴ y R²⁰ junto con los átomos de carbono a los que están unidos forman un -CH₂- o -CH₂-CH₂-; R²² es H, alquilo, cicloalquilo o alcoxicarbonilo; m es cero o 1; n es cero o 1; p es cero, 1 ó 2; o las sales farmacéuticamente aceptables.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12172528 | 2012-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR091464A1 true AR091464A1 (es) | 2015-02-04 |
Family
ID=48626047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130102125 AR091464A1 (es) | 2012-06-19 | 2013-06-17 | Compuestos biciclicos de tiofenilamida |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9604977B2 (es) |
| EP (1) | EP2861574B1 (es) |
| JP (1) | JP6215924B2 (es) |
| KR (1) | KR20150023804A (es) |
| CN (1) | CN104395301B (es) |
| AR (1) | AR091464A1 (es) |
| BR (1) | BR112014030474A2 (es) |
| CA (1) | CA2869232A1 (es) |
| ES (1) | ES2577306T3 (es) |
| MX (1) | MX2014014708A (es) |
| RU (1) | RU2644565C2 (es) |
| TW (1) | TW201402560A (es) |
| WO (1) | WO2013189841A1 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104693169A (zh) * | 2015-02-11 | 2015-06-10 | 佛山市赛维斯医药科技有限公司 | 一种硝基取代的甲氧苯噻吩酰胺类双靶点抑制剂及其用途 |
| CN104803946A (zh) * | 2015-03-03 | 2015-07-29 | 佛山市赛维斯医药科技有限公司 | 含腈基噻唑和环戊二烯结构的ptp1b抑制剂及其用途 |
| KR102749015B1 (ko) | 2017-06-06 | 2025-01-02 | 베리카 파마슈티컬스 인크. | 피부 장애의 치료 |
| USD900312S1 (en) | 2017-06-15 | 2020-10-27 | Verrica Pharmaceuticals, Inc. | Applicator |
| KR20230154094A (ko) | 2017-06-15 | 2023-11-07 | 베리카 파마슈티컬스 인크. | 신체 표면 장애의 치료를 위한 장치 |
| US20200270269A1 (en) * | 2017-10-04 | 2020-08-27 | Verrica Pharmaceuticals, Inc. | Synthesis of cantharidin |
| CN108191885B (zh) * | 2018-01-29 | 2020-08-04 | 华东师范大学 | 一类哌啶并噻吩类小分子有机化合物及其应用 |
| CN109884212A (zh) * | 2019-03-27 | 2019-06-14 | 清华大学深圳研究生院 | 基于化学衍生化与hplc-ms的不饱和脂肪酸定量方法 |
| MX2023000036A (es) | 2020-06-27 | 2023-02-01 | Crescenta Biosciences | Composicion de compuestos que modulan el metabolismo celular y metodos de uso. |
| US12138243B2 (en) | 2021-12-31 | 2024-11-12 | Crescenta Biosciences | Antiviral use of FABP4 modulating compounds |
| CN115636724A (zh) * | 2022-10-18 | 2023-01-24 | 浙大宁波理工学院 | 一种4-氟-4-甲基环己醇及其制备方法 |
| AU2024284676A1 (en) * | 2023-06-05 | 2026-01-08 | Celloram Inc. | Inhibitors of fatty acid binding proteins (fabps), methods of use and methods of making |
| US20250325529A1 (en) * | 2024-04-23 | 2025-10-23 | Celloram, Inc. | INHIBITORS OF FATTY ACID BINDING PROTEINS (FABPs), METHODS OF USE AND METHODS OF MAKING |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1670804A2 (en) * | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| US20050085531A1 (en) * | 2003-10-03 | 2005-04-21 | Hodge Carl N. | Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| US7772232B2 (en) * | 2004-04-15 | 2010-08-10 | Bristol-Myers Squibb Company | Quinazolinyl compounds as inhibitors of potassium channel function |
| EP1676834A1 (en) * | 2004-12-30 | 2006-07-05 | Sanofi-Aventis Deutschland GmbH | Fused bicyclic carboxamide derivates for use as CXCR2 inhibitors in the treatment of inflammation |
| CA2599987A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| US20100063065A1 (en) * | 2005-09-29 | 2010-03-11 | Inpharmatica Limited | Thiophene derivatives as ppar agonists i |
| WO2008000407A1 (en) * | 2006-06-28 | 2008-01-03 | Sanofi-Aventis | Inhibitors of cxcr2 |
| RU2364597C1 (ru) * | 2007-12-14 | 2009-08-20 | Андрей Александрович Иващенко | ГЕТЕРОЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ Hh-СИГНАЛЬНОГО КАСКАДА, ЛЕКАРСТВЕННЫЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ И СПОСОБ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С АББЕРАНТНОЙ АКТИВНОСТЬЮ Hh СИГНАЛЬНОЙ СИСТЕМЫ |
-
2013
- 2013-06-14 JP JP2015517697A patent/JP6215924B2/ja not_active Expired - Fee Related
- 2013-06-14 RU RU2014152350A patent/RU2644565C2/ru not_active IP Right Cessation
- 2013-06-14 ES ES13728748.8T patent/ES2577306T3/es active Active
- 2013-06-14 MX MX2014014708A patent/MX2014014708A/es unknown
- 2013-06-14 WO PCT/EP2013/062314 patent/WO2013189841A1/en not_active Ceased
- 2013-06-14 CA CA2869232A patent/CA2869232A1/en not_active Abandoned
- 2013-06-14 KR KR1020157001351A patent/KR20150023804A/ko not_active Ceased
- 2013-06-14 EP EP13728748.8A patent/EP2861574B1/en not_active Not-in-force
- 2013-06-14 BR BR112014030474A patent/BR112014030474A2/pt not_active Application Discontinuation
- 2013-06-14 CN CN201380031947.2A patent/CN104395301B/zh not_active Expired - Fee Related
- 2013-06-17 AR ARP130102125 patent/AR091464A1/es unknown
- 2013-06-18 TW TW102121602A patent/TW201402560A/zh unknown
-
2014
- 2014-12-18 US US14/574,950 patent/US9604977B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2861574A1 (en) | 2015-04-22 |
| BR112014030474A2 (pt) | 2017-06-27 |
| US9604977B2 (en) | 2017-03-28 |
| ES2577306T3 (es) | 2016-07-14 |
| RU2014152350A (ru) | 2016-08-10 |
| EP2861574B1 (en) | 2016-04-20 |
| RU2644565C2 (ru) | 2018-02-13 |
| TW201402560A (zh) | 2014-01-16 |
| JP2015520199A (ja) | 2015-07-16 |
| CN104395301A (zh) | 2015-03-04 |
| MX2014014708A (es) | 2015-02-24 |
| KR20150023804A (ko) | 2015-03-05 |
| HK1206340A1 (en) | 2016-01-08 |
| CA2869232A1 (en) | 2013-12-27 |
| WO2013189841A1 (en) | 2013-12-27 |
| JP6215924B2 (ja) | 2017-10-18 |
| US20150175594A1 (en) | 2015-06-25 |
| CN104395301B (zh) | 2017-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR091464A1 (es) | Compuestos biciclicos de tiofenilamida | |
| AR088989A1 (es) | Derivados biciclicos de dihidroisoquinolin-1-ona | |
| AR087984A1 (es) | Derivados biciclicos de dihidroquinolina-2-ona | |
| AR111776A1 (es) | Heteroarilos inhibidores de las proteínas ras mutantes de g12c | |
| AR087901A1 (es) | Derivados dihidroquinolina-2-ona como inhibidores de la aldosterona sintasa y procedimiento para su obtencion | |
| AR091261A1 (es) | Derivados de alcoholes 1-fenil-2-piridinilalquilicos como inhibidores de la fosfodiesterasa | |
| AR088014A1 (es) | Derivados de alcoholes 1-fenil-2-piridinil alquilicos como inhibidores de la fosfodiesterasa | |
| AR090678A1 (es) | Derivados de fenil-tetrahidroisoquinolina como inhibidores de la aldosterona-sintasa y un metodo para su sintesis | |
| AR097633A1 (es) | Pesticidas de azol bicíclico sustituido con heterociclos | |
| AR094684A1 (es) | Triterpenoides de c-19 modificados, con actividad inhibidora de la maduración del vih | |
| AR096643A1 (es) | Procedimiento de síntesis para la preparación de análogos macrocíclicos c1-ceto de halicondrina b e intermediarios útiles en la misma incluyendo intermediarios que contienen grupos -so₂-(p-tolilo) | |
| AR114083A2 (es) | AGENTES INDUCTORES DE APOPTOSIS CON SELECTIVIDAD POR Bcl-2 PARA EL TRATAMIENTO DE CÁNCER Y ENFERMEDADES INMUNES | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| AR110053A2 (es) | Modulación de receptores quimiosensoriales y ligandos relacionados con los mismos | |
| AR098492A1 (es) | Derivados de purina | |
| AR087747A1 (es) | Derivados de quinolona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR096330A1 (es) | Derivados del bipirazol como inhibidores jak | |
| AR110227A2 (es) | Derivados de pirazol con acción sobre fgf | |
| AR092496A1 (es) | Tiofenilamidas no anuladas | |
| AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
| AR101495A1 (es) | Compuestos condensados de 11 miembros y fungicidas agrícolas / hortícolas que los contienen | |
| AR124443A1 (es) | Compuestos y composición para el tratamiento de condiciones asociadas con cgas | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR099936A1 (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| AR113886A1 (es) | Derivados de indol macrocíclicos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |